Table 2.

Best response as assessed by the Independent Response Adjudication Committee (IRAC)

	Efficacy-evaluable population (n = 187)
Overall response (CR + VGPR + PR), n (%) [95% CI]	89 (47.6) [40.4–54.8]
CR, n (%)	7 (3.7)
PR, n (%)	82 (43.9)
VGPR, n (%)	23 (12.3)
Stable disease, n (%)	88 (47.1)
Progressive disease, n (%)	10 (5.3)
Median duration of response, months (range)	8.8 (0.4–18.8)
Median time to response, months (range)	1.9 (0.9–10.2)

Abbreviations: CR Complete response, PR Partial response, VGPR Very good partial response.